Recursion Pharmaceuticals, Inc.
RXRX
Rank in Stocks
#5373
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in... Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Share Price
$3.81
Last synced: 2026-11-09
Market Cap
$2.37B
Change (1 day)
8.10%
Change (1 year)
-19.21%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Recursion Pharmaceuticals, Inc. (RXRX)
Category
Healthcare
Operating Margin for Recursion Pharmaceuticals, Inc. (RXRX)
Operating Margin as of November 2026 TTM: -991.72%
According to Recursion Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -991.72%. At the end of 2025 the company had an operating margin of -867.87%.
Operating Margin history for Recursion Pharmaceuticals, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -991.72% | 14.27% |
| 2025 | -867.87% | 6.61% |
| 2024 | -814.09% | 2.04% |
| 2023 | -797.84% | 28.84% |
| 2022 | -619.26% | -66.12% |
| 2021 | -1,827.75% | -26.28% |
| 2020 | -2,479.20% | -32.07% |
| 2019 | -3,649.39% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.85% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.03% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Recursion Pharmaceuticals, Inc.'s operating margin
What is Recursion Pharmaceuticals, Inc.'s operating margin?
Recursion Pharmaceuticals, Inc.'s operating margin is -991.72%, as of Nov 2026.
What was Recursion Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Recursion Pharmaceuticals, Inc.'s operating margin was -867.87%, compared with -814.09% in 2024.
How has Recursion Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Recursion Pharmaceuticals, Inc.'s operating margin was highest in 2022 (-619.26%) and lowest in 2020 (-2,479.20%).
How does Recursion Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Recursion Pharmaceuticals, Inc.'s operating margin (-991.72%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.